TCR-engineered T Cells in Solid Tumors: IMA202-101
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The study purpose is to establish the safety and tolerability of IMA202 product in patients
with solid tumors that express melanoma-associated antigen 1 (MAGEA1).